Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli-Reference-Cited by-同舟云学术

Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli

Published:2010-09 Issue:9 Volume:54 Page:4006-4008
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Auer Simon¹,Wojna Alexandra²,Hell Markus¹

Affiliation:

1. Department of Hospital Epidemiology and Infection Control, Salzburg Medical University, Salzburg, Austria

2. Private Laboratories of Dr. Mustafa/Dr. Richter, Salzburg, Austria

Abstract

ABSTRACT An increase in extended-spectrum-β-lactamase (ESBL)-producing Escherichia coli has been observed in outpatient settings. Consequently, 100 ESBL-positive E. coli isolates from ambulatory patients with clinically confirmed urinary tract infections were collected by a single laboratory between October 2004 and January 2008. Antimicrobial susceptibility testing was carried out using the oral antibiotics fosfomycin, pivmecillinam, and nitrofurantoin and the parenteral antibiotic ertapenem. Susceptibility rates indicate that fosfomycin (97%), nitrofurantoin (94%), and pivmecillinam (85%) could be considered important oral treatment options.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01760-09

Reference22 articles.

1. Alhambra, A., J. A. Cuadros, J. Cacho, J. L. Gomez-Garces, and J. I. Alos. 2004. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J. Antimicrob. Chemother.53:1090-1094.

2. Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat

3. Chaudhary, U., and R. Aggarwal. 2004. Extended-spectrum lactamases (ESBL)—an emerging threat to clinical therapeutics. Indian J. Med. Microbiol.22:75-80.

4. CLSI M100-S17. 2007

5. de Cueto, M., J. R. Hernandez, L. Lopez-Cerero, C. Morillo, and A. Pascual. 2006. Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Enferm. Infecc. Microbiol. Clin.24:613-616.

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fosfomycin Susceptibility among Extended-spectrum βeta Lactamase (Esbl)-Producing Escherichia coli and Klebsiella pneumoniae Isolates Causing Uti in a Tertiary Care Center in Western India;Medical Journal of Dr. D.Y. Patil Vidyapeeth;2024-03

2. Antibiotic resistance and virulence profiles of Proteus mirabilis isolated from broiler chickens at abattoir in South Africa;Veterinary Medicine and Science;2024-02-15

3. Effectiveness of oral antibiotics in managing extended-spectrum B-lactamase urinary tract infections: A retrospective analysis;SAGE Open Medicine;2024-01

4. An insight into genes responsible for fosfomycin resistance among uropathogens of asymptomatic bacteriuria during pregnancy: A North Indian study;Access Microbiology;2023-12-01

5. A multicentre study to determine the in vitro efficacy of flomoxef against extended-spectrum beta-lactamase producing Escherichia coli in Malaysia;PeerJ;2023-11-28